Fermiscan Holdings

Fermiscan Holdings was an Australian biotechnology company focused on the development and commercialization of a non-invasive diagnostic test for breast cancer. The company's core technology utilized synchrotron X-ray diffraction to analyze changes in the molecular structure of hair, specifically alpha-keratin, which was claimed to correlate with the presence of breast cancer. Despite an initial public offering on the ASX and commercial launch in several markets, the test faced significant scientific scrutiny and failed to gain widespread clinical validation. The company eventually entered voluntary administration and was delisted following financial difficulties and the failure of its primary diagnostic product to meet clinical expectations.